Is multiple myeloma λ light chain type stage 1 complex karyotype serious?

Multiple myeloma λ light chain type stage 1 complex karyotype, belonging to an immunological subtype of multiple myeloma, is generally more serious. Specifics should be judged comprehensively according to the patient’s condition, physical condition, treatment plan and prognosis. Multiple myeloma λ light chain type is prone to cause impaired renal tubular function, thus impairing renal function. Multiple myeloma λ light chain type stage I complex karyotype can be divided into low, medium and high risk groups according to the prognosis. 1. Low-risk group: serum β2-MG <4.0 mg/L, PCLI <0.4%, expected median survival 48 months. 2. Intermediate-risk group: serum β2-MG <4.0 mg/L, 0.4% 4.0 mg/L, PCLI > 1%, expected median survival of 12 months. It should be noted that patients with multiple myeloma λ light chain type stage I complex karyotype receive regular treatment under the guidance of a physician, many patients are likely to survive for a long time, and it is recommended that patients establish confidence in treatment. Specific drugs include bortezomib, cyclophosphamide, lenalidomide and so on.